<DOC>
	<DOCNO>NCT01910168</DOCNO>
	<brief_summary>In single center study blood sample biomarker analysis collect patient spinal muscular atrophy . Up 21 mL blood drawn eligible patient single visit .</brief_summary>
	<brief_title>A Study Collect Blood Samples From Patients With Spinal Muscular Atrophy Biomarker Analysis</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<criteria>Selfidentified 5qautosomal recessive spinal muscular atrophy ( SMA ) type I , II III judge neurologist upon diagnosis Ability willingness provide blood sample Willingness ( patient patient 's parent legal guardian ) complete best ability questionnaire request specific clinical genetic information Able participate willing give write informed consent assent . Informed consent obtain patient , patient 's parent legal guardian . Any known genetic condition spinal muscular atrophy , unless interfere purpose study base Sponsor 's judgment Participation clinical trial ( except observational study ) within previous 14 day Donation blood significant blood loss within three month prior screen Concomitant disease condition could interfere , treatment might interfere , conduct study , would , opinion investigator , pose unacceptable risk patient study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>